CRDF Stock Overview
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.18 |
| 52 Week High | US$6.42 |
| 52 Week Low | US$0.94 |
| Beta | 1.97 |
| 1 Month Change | -29.27% |
| 3 Month Change | 180.54% |
| 1 Year Change | 171.43% |
| 3 Year Change | -56.55% |
| 5 Year Change | 21.16% |
| Change since IPO | -99.74% |
Recent News & Updates
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03
Recent updates
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year
Dec 02
Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market
Nov 24Shareholder Returns
| CRDF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.1% | 1.0% | 1.2% |
| 1Y | 171.4% | 0.7% | 24.9% |
Return vs Industry: CRDF exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CRDF exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| CRDF volatility | |
|---|---|
| CRDF Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRDF's share price has been volatile over the past 3 months.
Volatility Over Time: CRDF's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Mark Erlander | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers.
Cardiff Oncology, Inc. Fundamentals Summary
| CRDF fundamental statistics | |
|---|---|
| Market cap | US$186.30m |
| Earnings (TTM) | -US$41.46m |
| Revenue (TTM) | US$488.00k |
382.7x
P/S Ratio-4.5x
P/E RatioIs CRDF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDF income statement (TTM) | |
|---|---|
| Revenue | US$488.00k |
| Cost of Revenue | US$32.86m |
| Gross Profit | -US$32.37m |
| Other Expenses | US$9.10m |
| Earnings | -US$41.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | -6,632.99% |
| Net Profit Margin | -8,496.93% |
| Debt/Equity Ratio | 0% |
How did CRDF perform over the long term?
See historical performance and comparison